Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human
AUTOR(ES)
Pappagianis, D.
RESUMO
Candida lusitaniae associated with infection in a patient with acute myelogenous leukemia developed resistance to amphotericin B during systemic treatment of the patient. The organism, when isolated initially, was inhibited by 0.31 μg of amphotericin B per ml in yeast nitrogen base agar, but when isolated (20 days later) just antemortem and postmortem, required 100 and 50 μg/ml, respectively, for complete inhibition at 48 h.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352808Documentos Relacionados
- Disruption of Ergosterol Biosynthesis Confers Resistance to Amphotericin B in Candida lusitaniae
- Change in Colony Morphology of Candida lusitaniae in Association with Development of Amphotericin B Resistance
- Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.
- Fatal septicemia due to amphotericin B-resistant Candida lusitaniae.
- High-Frequency, In Vitro Reversible Switching of Candida lusitaniae Clinical Isolates from Amphotericin B Susceptibility to Resistance
